Effectiveness and tolerability of ezetimibe add-on therapy to a bile acid resin-based regimen for hypercholesterolemia.
Combination lipid-reducing therapy is increasingly used, particularly for the management of severe or combined dyslipidemia in patients at high risk for coronary heart disease. To assess the potential additive effects of combining the cholesterol absorption inhibitor ezetimibe with a bile acid resin (BAR), a prospective chart review was performed of 40 patients in whom ezetimibe 10 mg/day was added to a stable regimen that included a BAR. At an average follow-up of 107 +/- 57 days, ezetimibe coadministration significantly reduced total cholesterol by 18%, triglycerides by 14%, and low-density lipoprotein cholesterol by 19% (all p < or =0.03), without significantly changing high-density lipoprotein cholesterol, and the combination was well tolerated.
Xydakis
Antonios M
AM
Division of Endocrinology, Diabetes and Metabolism, Baylor College of Medicine, 6565 Fannin Street, Houston, TX 77030, USA.
Guyton
John R
JR
Chiou
Philip
P
Stein
Judy L
JL
Jones
Peter H
PH
Ballantyne
Christie M
CM
D000499:Allylamine / Q000031:analogs & derivatives* / Q000627:therapeutic use; D000924:Anticholesteremic Agents / Q000627:therapeutic use*; D001384:Azetidines / Q000627:therapeutic use*; D002792:Cholestyramine Resin / Q000627:therapeutic use; D000069472:Colesevelam Hydrochloride; D003084:Colestipol / Q000627:therapeutic use; D004359:Drug Therapy, Combination; D000069438:Ezetimibe; D005260:Female; D006801:Humans; D006937:Hypercholesterolemia / Q000188:drug therapy*; D008297:Male; D008875:Middle Aged; D011446:Prospective Studies; D016896:Treatment Outcome
D000924:Anticholesteremic Agents; D001384:Azetidines; D002792:Cholestyramine Resin; D000499:Allylamine; D000069438:Ezetimibe; D003084:Colestipol; D000069472:Colesevelam Hydrochloride